BIOMAT Database Logo BIOMAT Database Logo

Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. 1992

H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Department of Hematology, Anderson Cancer Center, Houston, Texas 77030.

OBJECTIVE Elevated serum beta-2 microglobulin (beta 2M) levels are associated with poor prognosis in several lymphoproliferative disorders including multiple myeloma and lymphoma. Their prognostic relevance in acute lymphocytic leukemia (ALL) is unknown. We analyzed the associations of serum beta 2M levels at diagnosis with pretreatment characteristics and with prognosis in adult ALL. METHODS One hundred fifty-nine adults with newly diagnosed ALL were investigated. Serum beta 2M levels were determined at diagnosis, on fresh peripheral blood samples, using a radioimmunoassay, the Pharmacia beta 2 Micro RIA (Pharmacia Diagnostics, Uppsala, Sweden). Statistical correlations were assessed by standard methods, and further independent prognostic value of serum beta 2M was determined by multivariate analysis. RESULTS Patients with beta 2M levels of 4.0 mg/L or above had a lower complete response rate (61% versus 80%; p = 0.02), a significantly worse survival (p < 0.01), and a significantly higher association with development of central nervous system (CNS) leukemia (p < 0.01). High beta 2M levels were more common among patients with older age, with elevated creatinine, bilirubin, and alkaline phosphatase levels, with low albumin levels, and with B-cell disease. Multivariate analysis for survival indicated the beta 2M level to be an independent prognostic variable (after adjusting for pretreatment creatinine level and age). The evaluation of beta 2M levels within low- and high-risk groups for CNS disease suggested an association of elevated beta 2M levels with a worse incidence of CNS disease in the high-risk patients. CONCLUSIONS Monitoring serum beta 2M levels may provide significant prognostic information in adults with ALL and should be included in their pretreatment evaluation. Its importance in childhood ALL requires investigation.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002173 Cancer Care Facilities Institutions specializing in the care of cancer patients. Hospitals, Cancer,Cancer Care Facility,Cancer Hospital,Cancer Hospitals,Facilities, Cancer Care,Facility, Cancer Care,Hospital, Cancer
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Serum beta 2-microglobulin in adult acute lymphocytic leukemia.
April 1994, The American journal of medicine,
H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Prognostic relevance of serum beta 2-microglobulin in acute myeloid leukemia.
October 1992, Leukemia,
H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
October 1983, European journal of cancer & clinical oncology,
H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Clinical significance of beta 2-microglobulin in serum of adult T cell leukemia.
April 1995, Leukemia,
H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Clinical significance of serum beta 2-microglobulin in leukemia.
October 1982, Bulletin of the Osaka Medical School,
H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Serum beta 2 microglobulin in adult myeloid acute leukemias.
April 1984, Blut,
H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
[Significance of serum levels of beta-2-microglobulin in dialysis patients].
September 1990, Recenti progressi in medicina,
H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Serum beta-2 microglobulin in chronic lymphocytic leukaemia.
January 1982, Clinical and laboratory haematology,
H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Serum beta-2 microglobulin in chronic lymphocytic leukaemia.
January 1985, Acta medica Hungarica,
H M Kantarjian, and T Smith, and E Estey, and A Polyzos, and S O'Brien, and S Pierce, and M Beran, and E Feldman, and M J Keating
Serum beta 2-microglobulin in patients with adult T-cell leukemia.
January 1991, Acta haematologica,
Copied contents to your clipboard!